Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Minieye Technology Co., Ltd
深圳佑駕創新科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2431)

VOLUNTARY ANNOUNCEMENT
ON-MARKET SHARE REPURCHASE

This announcement is made by Minieye Technology Co., Ltd (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors of the Company (the "**Board**") wishes to announce that the Board has resolved to repurchase the H shares of the Company (the "**H Shares**") in the open market on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") from time to time for an aggregate amount of up to HK$200 million (the "**Share Repurchase**") pursuant to the general mandate (the "**Share Repurchase Mandate**") granted to the directors of the Company (the "**Directors**") and approved by the shareholders of the Company (the "**Shareholders**") at the annual general meeting (the "**AGM**") held on May 23, 2025. The term of the Share Repurchase Mandate shall commence from consideration and approval at the AGM until the following dates (whichever is earlier): (i) the conclusion of the next AGM of the Company of which time it shall lapse unless, by special resolutions passed at that meeting, the mandate is renewed, either conditionally or subject to conditions; or (ii) the revocation or variation of the mandate under the resolution by a special resolution at any general meeting of the Company. Details of the Share Repurchase Mandate, together with the explanatory notes in connection therewith, are set out in the AGM circular of the Company dated April 29, 2025.

The Board shall conduct the Share Repurchase by exercising its powers granted to the Directors under the Share Repurchase Mandate and in compliance with the Articles of Association, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), the applicable laws of the People's Republic of China and all applicable laws, regulations and rules to which the Company is subject. The Share Repurchase may be conducted until the expiration date of the Share Repurchase Mandate or the date when the Board has approved to terminate the Share Repurchase or to revoke the mandate granted to the authorized persons pursuant to the relevant Board resolutions, whichever is earlier. The Company intends to finance the proposed Share Repurchase by its own financial resources (other than the proceeds raised from its global offering).

The Board believes that the Share Repurchase will demonstrate the Company's confidence in its own business outlook and prospects and would ultimately benefit the Company and create value for its Shareholders. The Board believes that the Company's current financial resources would enable it to implement the Share Repurchase while maintaining a solid financial position.

As of the date of this announcement, the Company has not repurchased any H Shares under the Share Repurchase Mandate. Shareholders and potential investors should note that the implementation of the on-market Share Repurchase by the Company will be subject to market conditions and will be conducted at the absolute discretion of the Board and/or its authorized person(s). There is no assurance of the timing, quantity or price of any repurchases or whether the Company will repurchase any shares at all. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Minieye Technology Co., Ltd
Dr. Liu Guoqing
Chairman of the Board, Executive Director and General Manager

Hong Kong, January 6, 2026

As at the date of this announcement, the Board comprises: (i) Dr. Liu Guoqing, Mr. Yang Guang, Mr. Zhou Xiang and Mr. Wang Qicheng, as executive directors; (ii) Mr. Bi Lei and Ms. Liu Yiran, as non-executive directors; and (iii) Dr. Xiang Yang, Mr. Tan Kaiguo and Dr. Tan Mingkui as independent non-executive directors.